Novel strategies to delineate matrix metalloproteinase (MMP)-substrate relationships and identify targets to block MMP activity.
Adverse extracellular matrix (ECM) remodeling contributes to fibrotic disorders in the kidney, lung, and heart. Matrix metalloproteinases (MMPs) are key enzymes regulating ECM turnover, and MMP inhibition attenuates remodeling. Recent technological developments allow MMP-substrate relationships to be identified and explored as novel therapeutic targets. This review summarizes current and novel strategies to block MMP activity.
Lindsey
M L
ML
Department of Medicine, Division of Cardiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA. lindseym@uthscsa.edu
D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D005109:Extracellular Matrix / Q000378:metabolism; D006801:Humans; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D040901:Proteomics; D013379:Substrate Specificity
D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases